Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 12, Number 8—August 2006

Research

Antibody Response to Pneumocystis jirovecii

Kieran R. Daly*†, Laurence Huang‡, Alison Morris§, Judy Koch*†, Kristina Crothers‡¶, Linda Levin†, Shary Eiser‡, Supriya Satwah†, Patrizia Zucchi‡#, and Peter D. Walzer*†Comments to Author 
Author affiliations: *Veterans Affairs Medical Center, Cincinnati, Ohio, USA; †University of Cincinnati, Cincinnati, Ohio, USA; ‡University of California, San Francisco, California, USA; §University of Southern California, Los Angeles, California, USA; ¶Yale University School of Medicine, New Haven, Connecticut, USA; #University of Pavia, Pavia, Italy

Main Article

Table 3

Antibody levels to major surface glycoprotein C in Pneumocystis pneumonia (PCP) patients by history of PCP and week of observation*

Week No history of PCP
History of PCP
n Geometric mean (95% CI) n Geometric mean (95% CI)
Baseline (0) 59 4.1 (2.8–6.0) 19 4.2 (2.0–9.0)
1–2 18 9.9 (4.6–21.5) 6 3.9 (0.5–30.8)
3–4 11 17.9 (5.9–53.6)† 6 3.0 (0.7–12.1)
5–6 13 4.4 (2.6–7.4) 4 1‡

*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.
†p<0.001 versus week 0.
‡Observed values were equal.

Main Article

TOP